Background: Meta-analyses have consistently concluded that a positive therapeutic alliance is associated with better clinical outcomes and progress. To date, however, very few studies have focused on sociodemographic or clinical patient characteristics as moderators of alliance. Method: A multicenter longitudinal treatment outcome study was conducted to investigate the associations of patient and clinician perceptions of the therapeutic alliance with improvement in depression, and to investigate whether these associations were influenced by sociodemographic or clinical characteristics of the patient. Clinician-rated Montgomery Åsberg Depressive Rating Scale scores and both patient- and therapist-rated Helping Alliance Questionnaire (HAQ-I) scores were obtained from 567 outpatients with major depressive disorder who received 6 months of combined psycho- and pharmacotherapy. Results: Multilevel repeated-measures analyses indicated that patient- and therapist-rated HAQ-I scores, 4 weeks after treatment began, positively predicted subsequent clinical change, controlling for the effect of early improvement and a range of patient characteristics. Next to alliance, early improvement, initial depressive symptom severity, a history of psychiatric disorders, and occupational status affected the rate of clinical improvement. Personality pathology comorbidity, marital and occupational status, and the atypical character of the major depressive episode (MDE) moderated the alliance-outcome relationship, depending on the informant (patient or therapist) of therapeutic alliance. Conclusions: The present findings suggest that therapist and patient ratings of therapeutic alliance predict therapeutic progress, and that this relation may be moderated by client characteristics, including personality pathology comorbidity, marital status, occupational status, and the atypical character of the MDE.

Keywords:
Major depressive disorder, Symptom improvement, Therapeutic alliance, Multilevel analysis
1.
Horvath AO, Symonds BD: Relation between working alliance and outcome in psychotherapy – a meta-analysis. J Couns Psychol 1991;38:139–149.
2.
Horvath AO, Bedi RP: The Alliance. New York, Oxford University Press, 2002.
3.
Martin DJ, Garske JP, Davis MK: Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol 2000;68:438–450.
4.
Bordin ES: The generalizability of the psychoanalytic concept of the working alliance. Psychother Theory Res Pract 1979;16:252–260.
5.
Constantino MJ, Castonguay LG, Schut AJ: The Working Alliance: A Flagship for the ‘Scientist-Practitioner’ Model in Psychotherapy. Boston, Allyn & Bacon, 2002.
6.
van Andel P, Erdman RAM, Karsdorp PA, Appels A, Trijsburg RW: Group cohesion and working alliance: prediction of treatment outcome in cardiac patients receiving cognitive behavioral group psychotherapy. Psychother Psychosom 2003;72:141–149.
7.
Lambert MJ, Ogles BM: The Efficacy and Effectiveness of Psychotherapy, ed 5. New York, Wiley, 2004.
8.
Lambert MJ, Archer A: Research Findings on the Effects of Psychotherapy and Their Implications for Practice. Washington, American Psychological Association, 2006.
9.
Wampold BE: Outcomes of Individual Counseling and Psychotherapy: Empirical Evidence Addressing Two Fundamental Questions, ed 3. New York, Wiley, 2000.
10.
Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang YH: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974–981.
11.
Klein DN, Schwartz JE, Santiago NJ, Vivian D, Vocisano C, Castonguay LG, Arnow B, Blalock JA, Manber R, Markowitz JC, Riso LP, Rothbaum B, McCullough JP, Thase ME, Borian FE, Miller IW, Keller MB: Therapeutic alliance in depression treatment: controlling for prior change and patient characteristics. J Consult Clin Psychol 2003;71:997–1006.
12.
Piper WE, Ogrodniezuk JS, Joyce AS: Quality of object relations as a moderator of the relationship between pattern of alliance and outcome in short-term individual psychotherapy. J Pers Assess 2004;83:345–356.
13.
Hox J: Multilevel Analysis: Techniques and Applications. Mahwah, Lawrence Erlbaum Associates, 2002.
14.
Rasbash J, Steele F, Browne W, Prosser B: A User’s Guide to MLwiN (version 2.0). 2004.
15.
Barber JP, Luborsky L, Crits-Christoph P, Thase ME, Weiss R, Frank A, Onken L, Gallop R: Therapeutic alliance as a predictor of outcome in treatment of cocaine dependence. Psychother Res 1999;9:54–73.
16.
Derubeis RJ, Feeley M: Determinants of change in cognitive therapy for depression. Cogn Ther Res 1990;14:469–482.
17.
Barber JP, Connolly MB, Crits-Christoph P, Gladis L, Siqueland L: Alliance predicts patients’ outcome beyond in-treatment change in symptoms. J Consult Clin Psychol 2000;68:1027–1032.
18.
Gaston L, Marmar CR, Gallagher D, Thompson LW: Alliance prediction of outcome beyond in-treatment symptomatic change as psychotherapy processes. Psychother Res 1991;1:104–113.
19.
Horvath AO: The alliance. Psychotherapy 2001;38:365–372.
20.
Kazdin AE: Methodology, Design, and Evaluation in Psychotherapy Research, ed 4. New York, Wiley, 1994.
21.
Montgomery SA, Åsberg M: New depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–389.
22.
Luborsky L, McLellan AT, Woody GE, Obrien CP, Auerbach A: Therapist success and its determinants. Arch Gen Psychiatry 1985;42:602–611.
23.
Gérin P, Dazord A, Sali AM: Psychothérapies et changements: Méthodologie de leur evaluation. Paris, PUF, 1991,
24.
Barber JP, Crits-Christoph P: Development of a therapist adherence/competence rating scale for supportive-expressive dynamic psychotherapy: a preliminary report. Psychother Res 1996;6:81–94.
25.
Carney MWP, Roth M, Carside RF: The diagnosis of depressive syndromes and the prediction of E.C.T. response. Br J Psychiatry 1965;111:659–674.
26.
Carney MWP, Sheffield BF: Depression and Newcastle scales – their relationship to Hamilton’s scale. Br J Psychiatry 1972;121:35–40.
27.
Castonguay LG, Beutler LE: Common and unique principles of therapeutic change: what do we know and what do we need to know?; in Castonguay LG, Beutler LE (eds): Principles of Therapeutic Change That Work. New York, Oxford University Press, 2006, pp 353–369.
28.
Beutler LE, Castonguay LG, Follette WC: Therapeutic factors in dysphoric disorders. J Clin Psychol 2006;62:639–647.
29.
Hersoug AG, Monsen JT, Havik OE, Hoglend P: Quality of early working alliance in psychotherapy: diagnoses, relationship and intrapsychic variables as predictors. Psychother Psychosom 2002;71:18–27.
30.
Zuroff DC, Blatt SJ: The therapeutic relationship in the brief treatment of depression: contributions to clinical improvement and enhanced adaptive capacities. J Consult Clin Psychol 2006;74:130–140.
31.
Mohr DC, Spring B, Freedland KE, Beckner V, Arean P, Hollon SD, Ockene J, Kaplan R: The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 2009;78:275–284.
32.
Westen D, Novotny CA, Thompson-Brenner H: The empirical status of empirically supported psychotherapies: assumptions, findings, and reporting in controlled clinical trials. Psychol Bull 2004;130:631–663.
33.
Okiishi J, Lambert MJ, Nielsen SL, Ogles BM: Waiting for supershrink: an empirical analysis of therapist effects. Clin Psychol Psychother 2003;10:361–373.
34.
Warden D, Trivedi MH, Wisniewski SR, Lesser IM, Mitchell J, Balasubramani GK, Fava M, Shores-Wilson K, Stegman D, Rush AJ: Identifying risk for attrition during treatment for depression. Psychother Psychosom 2009;78:372–379.
35.
Quilty LC, Godfrey KM, Kennedy SH, Bagby RM: Harm avoidance as a mediator of treatment response to antidepressant treatment of patients with major depression. Psychother Psychosom 2010;79:116–122.
36.
Kuyken W, Tsivrikos D: Therapist competence, comorbidity and cognitive-behavioral therapy for depression. Psychother Psychosom 2009;78:42–48.
37.
Ahn HN, Wampold BE: Where oh where are the specific ingredients? A meta-analysis of component studies in counseling and psychotherapy. J Couns Psychol 2001;48:251–257.
38.
Ackerman SJ, Hilsenroth MJ: A review of therapist characteristics and techniques positively impacting the therapeutic alliance. Clin Psychol Rev 2003;23:1–33.
39.
Stuart S, Noyes R: Interpersonal psychotherapy for somatizing patients. Psychother Psychosom 2006;75:209–219.
40.
Lazaratou H, Vlassopoulos M, Dellatolas G: Factors affecting compliance with treatment in an outpatient child psychiatric practice: a retrospective study in a community mental health centre in Athens. Psychother Psychosom 2000;69:42–49.
41.
Lazaratou H, Anagnostopoulos DC, Vlassopoulos M, Tzavara C, Zelios G: Treatment compliance and early termination of therapy: a comparative study. Psychother Psychosom 2006;75:113–121.
42.
Safran JD, Muran JC, Samstag LW, Winston A: Evaluating alliance-focused intervention for potential treatment failures: a feasibility study and descriptive analysis. Psychotherapy 2005;42:512–531.
43.
Safran JD, Muran JC: Has the concept of the therapeutic alliance outlived its usefulness? Psychotherapy 2006;43:286–291.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.